{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T03:28:30Z","timestamp":1763695710746,"version":"3.45.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vulvovaginal candidiasis (VVC) is a common gynecological complaint. Ibrexafungerp (brand name: Brexafemme\u00ae) is a new, first-in-class oral antifungal medication approved as a 1-day treatment for VVC and as a monthly treatment to reduce frequency of recurrent VVC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This article describes characteristics of patients who received ibrexafungerp and potential ibrexafungerp-related side effects in order to help inform optimal future use of this medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We used a large, national commercial health insurance claims database (the Merative\n                      <jats:sup>TM<\/jats:sup>\n                      MarketScan\u00ae Commercial\/Medicare Database) to identify female patients with one or more outpatient ibrexafungerp prescription during 1 July 2021 to 31 December 2023. We examined patient demographic characteristics, medical conditions and medications, type of healthcare provider seen, diagnostic testing performed, and potential ibrexafungerp side effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 1368 female patients who received ibrexafungerp, most were also prescribed fluconazole or topical antifungals (84.7%) or had one or more vaginitis\/vulvitis-related healthcare visit (76.9%) in the previous year. Few patients (2.9%) experienced a potential ibrexafungerp-related side effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results suggest that ibrexafungerp was generally used as non-first-line treatment for VVC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40801-025-00513-x","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T06:59:35Z","timestamp":1755327575000},"page":"563-567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Ibrexafungerp Use Patterns Among Patients with Commercial Health Insurance, United States, 2021\u20132023"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0458-2493","authenticated-orcid":false,"given":"Kaitlin","family":"Benedict","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dallas J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy A. W.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"issue":"1","key":"513_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12905-022-01741-x","volume":"22","author":"K Benedict","year":"2022","unstructured":"Benedict K, Singleton AL, Jackson BR, Molinari NAM. Survey of incidence, lifetime prevalence, and treatment of self-reported vulvovaginal candidiasis, United States, 2020. BMC Womens Health. 2022;22(1):147.","journal-title":"BMC Womens Health"},{"issue":"12","key":"513_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0278630","volume":"17","author":"K Benedict","year":"2022","unstructured":"Benedict K, Moret R, Molinari NAM, Jackson BR. Survey of healthcare providers\u2019 testing practices for vulvovaginal candidiasis and treatment outcomes-United States, 2021. PLoS ONE. 2022;17(12): e0278630.","journal-title":"PLoS ONE"},{"issue":"4","key":"513_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267866","volume":"17","author":"K Benedict","year":"2022","unstructured":"Benedict K, Lyman M, Jackson BR. Possible misdiagnosis, inappropriate empiric treatment, and opportunities for increased diagnostic testing for patients with vulvovaginal candidiasis-United States, 2018. PLoS ONE. 2022;17(4): e0267866.","journal-title":"PLoS ONE"},{"issue":"9","key":"513_CR4","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1093\/cid\/ciaa260","volume":"72","author":"SL Hillier","year":"2021","unstructured":"Hillier SL, Austin M, Macio I, Meyn LA, Badway D, Beigi R. Diagnosis and treatment of vaginal discharge syndromes in community practice settings. Clin Infect Dis. 2021;72(9):1538\u201343.","journal-title":"Clin Infect Dis"},{"issue":"Supplement_2","key":"513_CR5","doi-asserted-by":"publisher","first-page":"S162","DOI":"10.1093\/cid\/ciab1057","volume":"74","author":"P Nyirjesy","year":"2022","unstructured":"Nyirjesy P, Brookhart C, Lazenby G, Schwebke J, Sobel JD. Vulvovaginal candidiasis: a review of the evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections treatment guidelines. Clin Infect Dis. 2022;74(Supplement_2):S162\u20138.","journal-title":"Clin Infect Dis"},{"key":"513_CR6","doi-asserted-by":"crossref","unstructured":"Sobel R, Nyirjesy P, Ghannoum M, Delchev D, Azie N, Angulo D, et al. Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a\u2009global phase 3, randomised, placebo-controlled superiority study (VANISH 306). BJOG Int J Obstet Gynaecol. 2022;129(3):412\u201320.","DOI":"10.1111\/1471-0528.16972"},{"issue":"11","key":"513_CR7","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1093\/cid\/ciab750","volume":"74","author":"JR Schwebke","year":"2021","unstructured":"Schwebke JR, Sobel R, Gersten JK, Sussman SA, Lederman SN, Jacobs MA, et al. Ibrexafungerp versus placebo for vulvovaginal candidiasis treatment: a phase 3, randomized, controlled superiority trial (VANISH 303). Clin Infect Dis. 2021;74(11):1979\u201385.","journal-title":"Clin Infect Dis"},{"key":"513_CR8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2147\/DDDT.S339349","volume":"17","author":"NA Phillips","year":"2023","unstructured":"Phillips NA, Rocktashel M, Merjanian L. Ibrexafungerp for the treatment of vulvovaginal candidiasis: design, development and place in therapy. Drug Des Dev Ther. 2023;17:363\u20137.","journal-title":"Drug Des Dev Ther"},{"issue":"8","key":"513_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e28776","volume":"10","author":"R He","year":"2024","unstructured":"He R, Lin F, Yu B, Huang L. Efficacy and safety of ibrexafungerp in the treatment of vulvovaginal candidiasis: a meta-analysis of randomized controlled trials. Heliyon. 2024;10(8): e28776.","journal-title":"Heliyon"},{"key":"513_CR10","doi-asserted-by":"crossref","unstructured":"Flint ND, Rhoads JLW, Carlisle R, Ferrel M, Hopkins ZH, Secrest AM. The continued inappropriate use and overuse of combination topical clotrimazole-betamethasone. Dermatol Online J. 2021;27(8):1\u20139.","DOI":"10.5070\/D327854686"},{"issue":"1","key":"513_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.mm7301a1","volume":"73","author":"K Benedict","year":"2024","unstructured":"Benedict K, Smith DJ, Chiller T, Lipner SR, Gold JAW. Topical antifungal prescribing for Medicare Part D beneficiaries - United States, 2021. MMWR Morb Mortal Wkly Rep. 2024;73(1):1\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"513_CR12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jpeds.2017.03.031","volume":"186","author":"CM Wheat","year":"2017","unstructured":"Wheat CM, Bickley RJ, Hsueh YH, Cohen BA. Current trends in the use of two combination antifungal\/corticosteroid creams. J Pediatr. 2017;186:192-5.e1.","journal-title":"J Pediatr"},{"key":"513_CR13","unstructured":"LOTRISONE\u00ae(clotrimazole and betamethasone dipropionate) CREAM and LOTION. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2001\/18827s7s9s20s22lbl.pdf. Accessed 9 Dec 2024."},{"issue":"4","key":"513_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267866","volume":"17","author":"K Benedict","year":"2022","unstructured":"Benedict K, Lyman M, Jackson BR. Possible misdiagnosis, inappropriate empiric treatment, and opportunities for increased diagnostic testing for patients with vulvovaginal candidiasis\u2014United States, 2018. PLoS ONE. 2022;17(4): e0267866.","journal-title":"PLoS ONE"},{"issue":"8","key":"513_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss6808a1","volume":"68","author":"M Toda","year":"2019","unstructured":"Toda M, Williams SR, Berkow EL, Farley MM, Harrison LH, Bonner L, et al. Population-based active surveillance for culture-confirmed candidemia\u2014four sites, United States, 2012\u20132016. MMWR Surveill Summ. 2019;68(8):1\u201315.","journal-title":"MMWR Surveill Summ"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00513-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-025-00513-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00513-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T01:17:00Z","timestamp":1763687820000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-025-00513-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["513"],"URL":"https:\/\/doi.org\/10.1007\/s40801-025-00513-x","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"type":"print","value":"2199-1154"},{"type":"electronic","value":"2198-9788"}],"subject":[],"published":{"date-parts":[[2025,8,16]]},"assertion":[{"value":"31 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"No specific funding was received for this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"None of the authors have any competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This activity was reviewed by the CDC and was conducted consistent with applicable federal law and CDC policy (e.g., 45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C. \u00a7241(d); 5 U.S.C. \u00a7552a; 44 U.S.C. \u00a73501 et seq.). MarketScan data are fully de-identified, so this analysis was not subject to review by the CDC institutional review board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study used third-party data that we cannot legally distribute. All relevant summary data are within the article and the supporting files. The raw data underlying the results presented are available from the MerativeTM MarketScan\u00ae Research Databases:\n                      \n                      . Others can access the data by going to this website and contacting Merative. The authors did not have any special access privileges that others would not have.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: Kaitlin Benedict, Dallas J. Smith, Jeremy A.W. Gold; Formal analysis and investigation: Kaitlin Benedict; Writing \u2013 original draft preparation: Kaitlin Benedict; Writing \u2013 review and editing: Kaitlin Benedict, Dallas J. Smith, Jeremy A.W. Gold. All authors read and approved the final version.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}